Bone Sarcoma of the Spine

2009 ◽  
pp. 141-167 ◽  
Author(s):  
Klaus-Dieter Schaser ◽  
I. Melcher ◽  
A. Luzzati ◽  
A. C. Disch
Keyword(s):  
Bone Sarcoma

scholarly journals The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2478
Author(s):  
George N. Tzanakakis ◽  
Eirini-Maria Giatagana ◽  
Aikaterini Berdiaki ◽  
Ioanna Spyridaki ◽  
Kyoko Hida ◽  
...  
Keyword(s):  
Extracellular Matrix ◽  
Bone Sarcoma ◽  
Response To Therapy ◽  
Targeted Therapeutics ◽  
Attractive Therapeutic Target ◽  
Bone Sarcomas ◽  
Agent Development ◽  
Insulin Like Growth Factors ◽  
Igf Signaling

Bone sarcomas, mesenchymal origin tumors, represent a substantial group of varying neoplasms of a distinct entity. Bone sarcoma patients show a limited response or do not respond to chemotherapy. Notably, developing efficient chemotherapy approaches, dealing with chemoresistance, and preventing metastasis pose unmet challenges in sarcoma therapy. Insulin-like growth factors 1 and 2 (IGF-1 and -2) and their respective receptors are a multifactorial system that significantly contributes to bone sarcoma pathogenesis. Whereas failures have been registered in creating novel targeted therapeutics aiming at the IGF pathway, new agent development should continue, evaluating combinatorial strategies for enhancing antitumor responses and better classifying the patients that could best benefit from these therapies. A plausible approach for developing a combinatorial strategy is to focus on the tumor microenvironment (TME) and processes executed therein. Herewith, we will discuss how the interplay between IGF-signaling and the TME constituents affects sarcomas’ basal functions and their response to therapy. This review highlights key studies focusing on IGF signaling in bone sarcomas, specifically studies underscoring novel properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. Potential direct and adjunct therapeutical implications of the extracellular matrix (ECM) effectors will also be summarized.

Chemotherapy for Bone Sarcoma Does Not Affect Fertility Rates or Childbirth

2004 ◽  
Vol 428 ◽  
pp. 256-260 ◽  
Author(s):  
Harish S Hosalkar ◽  
Kathleen M Henderson ◽  
Arthur Weiss ◽  
Rakesh Donthineni ◽  
Richard D Lackman
Keyword(s):  
Bone Sarcoma ◽  
Fertility Rates

Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II – Study of the EORTC Soft Tissue and Bone Sarcoma Group

2007 ◽  
Vol 43 (6) ◽  
pp. 1017-1022 ◽  
Author(s):  
P. Reichardt ◽  
O.S. Nielsen ◽  
S. Bauer ◽  
J.T. Hartmann ◽  
P. Schöffski ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Bone Sarcoma ◽  
Adult Patients ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Imaging of Bone Sarcomas and Soft-Tissue Sarcomas

2021 ◽  
Author(s):  
Jasminka Igrec ◽  
Michael H. Fuchsjäger
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Bone Cancer ◽  
Bone Sarcoma ◽  
Daily Practice ◽  
Imaging Evaluation ◽  
Key Points ◽  
Bone Sarcomas ◽  
Publication Period ◽  
Ct And Mri

Background In the diagnosis of bone and soft-tissue sarcomas, the continuous advancement of various imaging modalities has improved the detection of small lesions, surgical planning, assessment of chemotherapeutic effects, and, importantly, guidance for surgery or biopsy. Method This review was composed based on a PubMed literature search for the terms “bone sarcoma,” “bone cancer” and “soft tissue sarcoma,” “imaging,” “magnetic resonance imaging”, “computed tomography”, “ultrasound”, “radiography”, and “radiomics” covering the publication period 2005–2020. Results and Conclusion As discussed in this review, radiography, ultrasound, CT, and MRI all play key roles in the imaging evaluation of bone and soft-tissue sarcomas. In daily practice, advanced MRI techniques complement standard MRI but remain underused, as they are considered time-consuming, technically challenging, and not reliable enough to replace biopsy and histology. PET/MRI and radiomics have shown promise regarding the imaging of sarcomas in the future. Key Points:  Citation Format

Longer duration of symptoms at the time of presentation is not associated with worse survival in primary bone sarcoma

2018 ◽  
Vol 100-B (5) ◽  
pp. 652-661 ◽  
Author(s):  
J. M. Lawrenz ◽  
J. F. Styron ◽  
M. Parry ◽  
R. J. Grimer ◽  
N. W. Mesko
Keyword(s):  
Overall Survival ◽  
Proportional Hazards ◽  
Bone Sarcoma ◽  
Axial Skeleton ◽  
Cox Proportional Hazards ◽  
Low Grade ◽  
Duration Of Symptoms ◽  
Negative Effect ◽  
Primary Bone Sarcoma ◽  
Primary Bone

Aims The primary aim of this study was to determine the effect of the duration of symptoms (DOS) prior to diagnosis on the overall survival in patients with a primary bone sarcoma. Patients and Methods In a retrospective analysis of a sarcoma database at a single institution between 1990 and 2014, we identified 1446 patients with non-metastatic and 346 with metastatic bone sarcoma. Low-grade types of tumour were excluded. Our data included the demographics of the patients, the characteristics of the tumour, and the survival outcome of patients. Cox proportional hazards analysis and Kaplan–Meier survival analysis were performed, and the survivorship of the non-metastatic and metastatic cohorts were compared. Results In the non-metastatic cohort, a longer DOS was associated with a slightly more favourable survival (hazard ratio (HR) 0.996, 95% confidence interval (CI) 0.994 to 0.998, p < 0.001). In all types of tumour, there was no difference in survival between patients with a DOS of greater than four months and those with a DOS of less than four months (p = 0.566). There was no correlation between the year of diagnosis and survival (p = 0.741). A diagnosis of chondrosarcoma (HR 0.636, 95% CI 0.474 to 0.854, p = 0.003) had the strongest positive effect on survival, while location in the axial skeleton (HR 1.76, 95% CI 1.36 to 2.29, p < 0.001) had the strongest negative effect on survival. Larger size of tumour (HR 1.05, 95% CI 1.03 to 1.06, p < 0.001) and increased age of the patient (HR 1.02, 95% CI 1.01 to 1.03, p < 0.001) had a slightly negative effect on survival. Metastatic and non-metastatic cohorts had similar median DOS (16 weeks, p = 0.277), although the median survival (15.5 months vs 41 months) and rates of survival at one year (69% vs 89%) and five years (20% vs 59%) were significantly shorter in the metastatic cohort. Conclusion A longer DOS prior to diagnosis is not associated with a poorer overall survival in patients with a primary bone sarcoma. Location in the axial skeleton remains the strongest predictor of a worse prognosis. This may be helpful in counselling patients referred for evaluation on a delayed basis. Cite this article: Bone Joint J 2018;100-B:652–61.

3D-Printed Cutting Guides for Resection of Long Bone Sarcoma and Intercalary Allograft Reconstruction

Orthopedics ◽  
2021 ◽  
pp. 1-7
Author(s):  
Matthew A. Gasparro ◽  
Charles A. Gusho ◽  
Obianuju A. Obioha ◽  
Matthew W. Colman ◽  
Steven Gitelis ◽  
...  
Keyword(s):  
Bone Sarcoma ◽  
Long Bone ◽  
Allograft Reconstruction ◽  
Cutting Guides ◽  
3D Printed
Sign in / Sign up

Export Citation Format

Share Document